GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (TSE:4502) » Definitions » Price-to-Owner-Earnings

Takeda Pharmaceutical Co (TSE:4502) Price-to-Owner-Earnings : 16.98 (As of Apr. 28, 2024)


View and export this data going back to 1949. Start your Free Trial

What is Takeda Pharmaceutical Co Price-to-Owner-Earnings?

As of today (2024-04-28), Takeda Pharmaceutical Co's share price is 円4089.00. Takeda Pharmaceutical Co's Owner Earnings per Share (TTM) ended in Dec. 2023 was 円240.84. It's Price-to-Owner-Earnings for today is 16.98.


The historical rank and industry rank for Takeda Pharmaceutical Co's Price-to-Owner-Earnings or its related term are showing as below:

TSE:4502' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.7   Med: 14.09   Max: 90.13
Current: 16.98

During the past 13 years, the highest Price-to-Owner-Earnings of Takeda Pharmaceutical Co was 90.13. The lowest was 4.70. And the median was 14.09.


TSE:4502's Price-to-Owner-Earnings is ranked better than
69.12% of 421 companies
in the Drug Manufacturers industry
Industry Median: 27.58 vs TSE:4502: 16.98

As of today (2024-04-28), Takeda Pharmaceutical Co's share price is 円4089.00. Takeda Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円112.61. Therefore, Takeda Pharmaceutical Co's PE Ratio for today is 36.31.

As of today (2024-04-28), Takeda Pharmaceutical Co's share price is 円4089.00. Takeda Pharmaceutical Co's EPS without NRI for the trailing twelve months (TTM) ended in was 円112.61. Therefore, Takeda Pharmaceutical Co's PE Ratio without NRI for today is 36.31.

During the past 13 years, Takeda Pharmaceutical Co's highest PE Ratio without NRI was 537.91. The lowest was 10.22. And the median was 30.70.


Takeda Pharmaceutical Co Price-to-Owner-Earnings Historical Data

The historical data trend for Takeda Pharmaceutical Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Price-to-Owner-Earnings Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.03 10.13 5.90 6.62 8.88

Takeda Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.23 8.88 9.25 11.29 16.83

Competitive Comparison of Takeda Pharmaceutical Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takeda Pharmaceutical Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Price-to-Owner-Earnings falls into.



Takeda Pharmaceutical Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Takeda Pharmaceutical Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4089.00/240.84
=16.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co  (TSE:4502) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Takeda Pharmaceutical Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (TSE:4502) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (TSE:4502) Headlines

No Headlines